GoodRx Holdings, Inc.

GoodRx Holdings, Inc. announced that Christopher McGinnis will transition from his role as Chief Financial Officer & Treasurer, effective August 5, 2026. His departure is not due to any disagreements with the company. The Board of Directors appointed Justin Fengler, the current Chief Strategy & Operations Officer, to also serve as CFO & Treasurer, effective August 6, 2026. Mr. Fengler will receive equity awards totaling $1.2 million and a $100,000 cash payment in connection with his appointment.

GoodRx Holdings, Inc. reported a decline in its second quarter and first half 2026 financial results. Q2 revenue decreased to $200.4 million from $203.1 million year-over-year, with net income falling to $8.5 million and diluted EPS to $0.02. For the first six months of 2026, revenue was $394.4 million, down from $406.0 million in the prior year, and net income was $9.7 million. Despite the revenue and net income decline, net cash provided by operating activities increased to $92.7 million for the first half of 2026, and total assets grew significantly to $2.34 billion.

GoodRx Holdings, Inc. reported Q2 2026 revenue of $200.4 million, a 1% decrease year-over-year, with net income at $8.5 million. Despite a decline in prescription transactions revenue, the company saw strong growth in its strategic areas, with Pharma Direct revenue increasing 76% and subscription revenue rising 39%. Management raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing strong first-half performance and progress in scaling Pharma Direct and subscriptions.

GoodRx Holdings, Inc. reported a substantial decline in its first-quarter 2026 financial results, with net income plummeting to $1.17 million from $11.05 million in the prior year. Revenue also decreased by 4.4% to $194.01 million. The company's diluted earnings per share fell to $0.00, down from $0.03. Additionally, GoodRx is navigating ongoing legal proceedings related to a consumer privacy class action, with a proposed $25.0 million settlement still awaiting court approval.

GoodRx Holdings, Inc. reported first-quarter 2026 financial results with revenue of $194.0 million, a 4% decrease year-over-year, and net income of $1.2 million. Despite the overall revenue decline, the company saw significant growth in its strategic areas, with Pharma Direct revenue increasing 82% to $52.2 million and subscription revenue rising 16% to $24.4 million. Based on a strong start to the year, GoodRx raised its full-year 2026 revenue guidance to $765-$785 million and Adjusted EBITDA expectations to over $235 million.

GoodRx Holdings, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, June 16, 2026. Stockholders will vote on the election of three Class III Directors, the ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory approval of named executive officer compensation. KPMG LLP was appointed on March 14, 2026, replacing PricewaterhouseCoopers LLP.

GoodRx Holdings, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, June 16, 2026, at 12:00 p.m. Pacific Time. Stockholders will vote on the election of three Class III Directors, the ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 (replacing PwC), and the advisory approval of named executive officer compensation. The record date for voting is April 20, 2026.

GoodRx Holdings, Inc. announced the appointment of Thomas Chan as its Chief Accounting Officer, effective April 23, 2026. Mr. Chan, 40, has been with GoodRx since October 2020, most recently serving as Vice President, Corporate Controller. In connection with his new role, his annual base salary will be $310,000, with a target annual bonus of 40% of his base salary, along with RSU and PSU awards totaling $175,000.